Spurred by the discoveries of human pluripotent stem cell culture by James Thomson in the 1990s and the induction of pluripotency from adult cells by Shinya Yamanaka in the 2000s, therapeutics derived ...
Solid Biosciences’ SGT-003 is the only late‑stage program to show early cardiac benefit across biomarkers and function, according to William Blair.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results